Hemangiomas and β-Blockers: On the Rebound

Mancini, Anthony J.

doi:10.1542/peds.2015-3739

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, adjuvant therapies such as beta-blockers, chemotherapy and laser treatment are frequently employed as supplementary treatments prior to considering surgical intervention. 6,30,31 Given the young age of the patients, the inherent risks and adverse effects associated with the mentioned therapeutic modalities are self-evident. Currently, the anticancer properties of fucoidan have been substantiated in their ability to selectively target receptors or signalling molecules in diverse cell populations, including tumour cells and immune cells.…”

Section: Discussionmentioning

confidence: 99%

“…However, the surgical approach carries substantial risks and potential for functional debilitation in cases where the lesions infiltrate critical blood vessels, nerves, or organs. Therefore, adjuvant therapies such as beta‐blockers, chemotherapy and laser treatment are frequently employed as supplementary treatments prior to considering surgical intervention 6,30,31 . Given the young age of the patients, the inherent risks and adverse effects associated with the mentioned therapeutic modalities are self‐evident.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to surgical removal of vascular tumours, drug therapy is commonly used as an adjunctive treatment. One common approach is the use of beta‐blockers, propranolol, a first‐line oral medication for treating infantile hemangiomas 6,7 . However, given that vascular tumours are commonly seen in infants, the choice of drug for children should be carefully considered, with a focus on minimizing potential adverse effects.…”

Section: Introductionmentioning

confidence: 99%

“…One common approach is the use of beta-blockers, propranolol, a first-line oral medication for treating infantile hemangiomas. 6,7 However, given that vascular tumours are commonly seen in infants, the choice of drug for children should be carefully considered, with a focus on minimizing potential adverse effects. Recent reports have highlighted severe adverse reactions to propranolol, including hypotension, hypoglycaemia and bronchospasm.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Fucoidan suppresses proliferation and epithelial‐mesenchymal transition process via Wnt/β‐catenin signalling in hemangioma

Zhu,

Luo,

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Hemangioma is a common benign tumour that usually occurs on the skin of the head and neck, particularly among infants. The current clinical treatment against hemangioma is surgery excision, however, application of drug is a safer and more economical therapy for children suffering from hemangioma. As a natural sulfated polysaccharide rich in brown algae, fucoidan is widely recognized for anti‐tumour bioactivity and dosage safety in humans. This study aims to demonstrate the anti‐tumour effect and underlying mechanism of fucoidan against hemangioma in vivo and in vitro. We investigated the effects of fucoidan by culturing hemangioma cells in vitro and treating BALB/c mice bearing with hemangioma. At first, we measured the cell proliferation and migration ability through in vitro experiments. Then, we tested the expression of epithelial‐mesenchymal transition (EMT) and Wnt/β‐catenin pathway‐related biomarkers by western blot and qPCR. Furthermore, we applied β‐catenin‐specific inhibitor, XAV939, to determine whether fucoidan suppressed EMT via the Wnt/β‐catenin pathway in hemangioma cells. In vivo experiments, we applied oral gavage of fucoidan to treat EOMA‐bearing mice, along with evaluating the safety and efficacy of fucoidan. We found that fucoidan remarkably inhibits the proliferation and EMT ability of hemangioma cells, which is dependent on the Wnt/β‐catenin pathway. These results suggest that fucoidan exhibits tumour inhibitory effect on aggressive hemangioma via regulating the Wnt/β‐catenin signalling pathway both in vitro and in vivo, providing a new potent drug candidate for treating hemangioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Fucoidan suppresses proliferation and epithelial‐mesenchymal transition process via Wnt/β‐catenin signalling in hemangioma

Zhu,

Luo,

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study

Baruch,

Ben Amitai,

Friedland

2024

Dermatology

View full text Add to dashboard Cite

Introduction: Propranolol is the first-line treatment for complicated infantile hemangioma (IH). Rebound growth following propranolol discontinuation is reported in 6–25% of patients. Atenolol is considered an effective alternative to propranolol. We aimed to compare the incidence of IH rebound growth following discontinuation of atenolol and propranolol and to identify associated risk factors. Methods: We reviewed the medical records of all the patients diagnosed with IH and treated with oral propranolol or atenolol during 2009–2019 in our tertiary center. Inclusion criteria were completion of at least 3 months of initial treatment and at least 3 months of follow-up after discontinuation of initial treatment. Results: Of 445 patients in total, 267 (60%) were treated with propranolol and 178 (40%) with atenolol. The incidence of rebound growth was similar between the groups: 59 (22.1%) and 40 (22.5%), respectively. Patients treated with atenolol required a shorter duration of treatment after rebound growth until growth arrest (9.41 ± 5.61 vs. 14.79 ± 10.02 months, p < 0.001). For the patients who initiated atenolol before the age of 5 months, the adjusted odds ratio (aOR) for regrowth was 0.6 (95% CI: 0.33–1.08). As duration of treatment increased, the risk of rebound growth increased; the aOR was 1.24 (95% CI: 1.10–1.38). No other significant risk factors for rebound growth were identified. Conclusions: The incidence of rebound growth was similar following treatment with two oral β-receptor blockers. Treatment initiation after the age of 5 months and long duration of treatment may increase the risk for regrowth. These findings should be further investigated as they may impact clinical decisions on treating IH.

show abstract

Propranolol as a First-line Treatment for Pediatric Hemangioma: Outcome of a Single Institution Over One Year

Kim

Min

Jung

et al. 2016

Clin Pediatr Hematol Oncol

View full text Add to dashboard Cite

Hemangiomas and β-Blockers: On the Rebound

Cited by 3 publications

References 12 publications

Fucoidan suppresses proliferation and epithelial‐mesenchymal transition process via Wnt/β‐catenin signalling in hemangioma

Fucoidan suppresses proliferation and epithelial‐mesenchymal transition process via Wnt/β‐catenin signalling in hemangioma

Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study

Propranolol as a First-line Treatment for Pediatric Hemangioma: Outcome of a Single Institution Over One Year

Contact Info

Product

Resources

About